Heterologous vaccine regimens against COVID-19
- PMID: 34181881
- PMCID: PMC8233006
- DOI: 10.1016/S0140-6736(21)01442-2
Heterologous vaccine regimens against COVID-19
Comment on
-
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.Lancet. 2021 Jul 10;398(10295):121-130. doi: 10.1016/S0140-6736(21)01420-3. Epub 2021 Jun 25. Lancet. 2021. PMID: 34181880 Free PMC article. Clinical Trial.
References
-
- European Medicines Agency AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. April 7, 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-find...
-
- European Medicines Agency COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis. June 11, 2021. https://www.ema.europa.eu/en/news/covid-19-vaccines-update-ongoing-evalu...
-
- European Centre for Disease Prevention and Control . European Centre for Disease Prevention and Control; Stockholm: 2021. Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. 18 May 2021.
-
- Medicines and Healthcare products Regulatory Agency Coronavirus vaccine—weekly summary of Yellow Card reporting. June 10, 2021. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical